Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.
Adult
Drug Interactions
Female
Genotype
Healthy Volunteers
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ pharmacokinetics
Indoleacetic Acids
/ pharmacology
Liver-Specific Organic Anion Transporter 1
/ genetics
Male
Middle Aged
Organic Anion Transporters
Pharmacogenetics
Pyridines
/ pharmacology
Receptors, Immunologic
/ antagonists & inhibitors
Receptors, Prostaglandin
/ antagonists & inhibitors
Rosuvastatin Calcium
/ pharmacokinetics
Simvastatin
/ pharmacokinetics
Drug-drug interactions
Fevipiprant
Organic anion transporting polypeptide
Pharmacogenetics
Prostaglandin D(2) receptor 2 antagonist
Statin
Journal
Pulmonary pharmacology & therapeutics
ISSN: 1522-9629
Titre abrégé: Pulm Pharmacol Ther
Pays: England
ID NLM: 9715279
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
28
11
2018
revised:
23
04
2019
accepted:
27
05
2019
pubmed:
14
6
2019
medline:
16
4
2020
entrez:
14
6
2019
Statut:
ppublish
Résumé
Fevipiprant, a prostaglandin D
Identifiants
pubmed: 31195091
pii: S1094-5539(18)30283-9
doi: 10.1016/j.pupt.2019.101809
pii:
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Indoleacetic Acids
0
Liver-Specific Organic Anion Transporter 1
0
Organic Anion Transporters
0
Pyridines
0
Receptors, Immunologic
0
Receptors, Prostaglandin
0
SLCO1B1 protein, human
0
fevipiprant
2PEX5N7DQ4
Rosuvastatin Calcium
83MVU38M7Q
Simvastatin
AGG2FN16EV
prostaglandin D2 receptor
XZF106QU24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101809Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.